Yann GODFRIN, Ph.D.
Chief Executive Officer
20+ years of experience in management of Biopharmaceutical companies focused product development from bench to Phase III clinical trial. Dr Godfrin was co-Founder, former CEO and CSO of ERYTECH Pharma (EPA/NASDAQ: ERYP) and former CEO of Hemoxymed Europe. In addition to his entrepreurship, Dr Godfrin is an expert in pre-clinical and clinical product development strategy and has been consultant for several biopharmaceutical companies. He is the inventor of more than 15 patents families and several scientific publications. Dr Godfrin holds a Ph.D. degree in Health & Life Sciences (University of Nantes, France), an Engineer degree in Biomedical Sciences (University of Compiègne, France) and a Master degree in Pharmaceutical Drug Development (University of Lyon, France).
The supervisory board is non-executive, advise and control the executive board of the company.
President of the Supervisory Board
+20 years of experience in Business Development, especially in Biotech/Biopharma area. Mr Goineau was co-Founder and former CEO and COO of Erytech Pharma (EPA/NASDAQ: ERYP), former President of the association France Biotech, and is currently member of several supervisory boards.
Representative of Sofimac Partners
+25 years of experience as entrepreneur and in risk capital investment in biotech companies. François is graduated in biological engineering from UPEC Paris XII, in corporate finance at INSEAD and was an auditor at the IHDEN.
He is Senior Partner in the Technological Team and Member of the Management Board of Sofimac Partners.
Foucauld DE TINGUY DU POUET
Representative of GTP
Foucauld de Tinguy du Pouet (HEC), founded a bank specialized in financial enginnering and in bond and share arbitrage. He later was executive director of the largest independent French financial analysis company.
Luca BOLLIGER, Ph.D.
20+ years of experience in the pharmaceutical industry. First as Global discovery portfolio manager at Hoffmann-La Roche Ltd. He then pursued his career in the financial industry as a Fundamental analyst at BT&T asset management. He established Biopolo Ticino before becoming Director Business Development at Actelion. Luca Bolliger joined Recordati from Novimmune where he is VP and Director Corporate Licensing.